white → pink1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
25E-NBOH
2-(4-Ethyl-2,5-dimethoxyphenyl)-N-(2-hydroxybenzyl)ethanamine
2C-E-NBOH, NBOH-2C-E
25E-NBOH is a synthetic psychedelic of the substituted phenethylamine class, specifically an N-benzylated derivative of 2C-E.citation needed It was first developed by Martin Hansen at the University of Copenhagen in 2010 for use as a brain imaging agent. It has since appeared as a designer drug, first identified on seized blotter paper in Brazil in 2018. 25E-NBOH is reported to share most properties with 25E-NBOMe but with moderately reduced potency and a shorter duration.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~100 μg
Light100-600 μg
Moderate600-1000 μg
Strong1000-1200 μg
Heavy1200+ μg
Produces a strong, unpleasant metallic chemical taste and a distinct numbness of the tongue and mouth that can persist for up to an hour. Associated with a significant body load manifesting as vasoconstriction. Most samples found are not consistently dosed and are observed to have hotspots. It is highly advised to start at a lower dosage.
Duration
Onset15-45 minutes
Come Up30-60 minutes
Peak2-4 hours
Offset1-3 hours
After Effects1-12 hours
Total4-8 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
25E-NBOH is a potent serotonergic psychedelic of the NBOH series, producing an experience in which visual effects tend to dominate over the headspace. As with related N-benzyl phenethylamines, users generally describe pronounced open- and closed-eye visuals accompanied by physical stimulation, with a mental state that is comparatively mild relative to the intensity of the sensory effects. Detailed first-hand documentation of this compound remains limited, and its full subjective profile is not well characterized.
Physical
The body experience is stimulating, and users of NBOH-series compounds commonly report physical tension alongside the energetic body feel.
Cognitive
The headspace is generally described as lighter and less profound than that of classical psychedelics, with stimulation-tinged euphoria commonly reported.
Visual
Visual effects are the defining feature of the NBOH series and are reported as vivid and dose-dependent.
Distortions
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
In vitro, 25E-NBOH (compound 8b) bound human 5-HT2A receptors with a Ki of 0.29 nM and rat 5-HT2C receptors with a Ki of approximately 3.4 nM, corresponding to an 11.7-fold binding preference for 5-HT2A in that assay.1 In human-receptor phosphoinositide-hydrolysis assays, its pEC50 values were 8.89 ± 0.10 at 5-HT2A and 7.42 ± 0.13 at 5-HT2C, with intrinsic activities of 94 ± 5% and 98 ± 2% of the serotonin response, respectively.citation needed These in-vitro measurements do not establish a human dose-response or safety profile.
Pharmacokinetics
No controlled human pharmacokinetic profile has been published. However, metabolism is not wholly unknown: LC-HRMS molecular networking of plasma and urine from one severe intoxication involving both 25E-NBOH and MDPHP proposed seven 25E-NBOH metabolites—two phase I ions and five phase II ions.2 The authors reported M6 (m/z 492.223) as the most intense 25E-NBOH-related ion in both matrices and proposed it as a possible consumption marker.2 Because this was a single mixed-exposure case and the structures were proposed by molecular-networking evidence, the findings do not provide population pharmacokinetic parameters or definitive reference-standard confirmation of every metabolite.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance to the effects of 25E-NBOH develops almost immediately following ingestion.
Baseline Reset
2-4 days to return to baseline tolerance in the absence of further consumption.
Half Tolerance
Approximately 1-2 days for tolerance to reduce to half of its peak level.
Cross Tolerance
Serotonergic psychedelics (cross-tolerance is present but not uniform across all compounds; some psychedelics may be significantly affected while others experience only slight reduction in effects)
Harm Potential
Addiction & Dependence
Psychological
Extremely LowAnecdotal reports suggest 25E-NBOH is non-habit-forming, consistent with classical psychedelics. The desire to use it may actually decrease with repeated use.
Toxicity
Cardiovascular
Acute cardiovascular effects including vasoconstriction, elevated blood pressure, and increased heart rate have been reported during intoxication; vasoconstriction contributes to the substance's notable body load, often manifesting as muscle soreness and tension.citation needed
Psychosis Risk
Individuals with bipolar disorder or schizoaffective disorder are at elevated risk of experiencing a psychotic episode and are strongly advised to avoid this substance.
Seizure Risk
Seizures are rarely observed but represent a risk in predisposed individuals, particularly when combined with physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.
History & Culture
25E-NBOH was first synthesized in 2010 by Martin Hansen at the University of Copenhagen, where it was developed as a brain imaging agent for research purposes.citation needed The compound was part of a broader effort to create selective serotonin receptor ligands suitable for neuroimaging…
Legality
By Country
Illegal1
United KingdomClass AControlled under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause, which covers structurally related compounds regardless of specific scheduling.4 Class A classification carries the most severe penalties under UK drug law, including up to seven years imprisonment for possession and life imprisonment for supply offenses.5
Not scheduled1
United StatesUnscheduled (Analogue Act applies)Not explicitly listed under the Controlled Substances Act of 1970. However, due to structural similarity to NBOMe-class compounds, it may be prosecuted under the Federal Analogue Act of 1986 when sold or possessed for human consumption, effectively treating it as a Schedule I substance.6 Manufacturing, purchasing, possessing, or distributing without DEA authorization could result in federal prosecution.
References
Source Pages
Citations
- Martin Hansen, Karina Phonekeo, James S. Paine, Sebastian Leth-Petersen, Mikael Begtrup, Hans Bräuner-Osborne, & Jesper L. Kristensen. (March 2014). Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chemical Neuroscience, 5(3), 243–9. https://doi.org/10.1021/cn400216u12
- Romain Pelletier, Thomas Gicquel, Julien Carvelli, Pierre Balaz, Anne-Laure Pelissier-Alicot, Isabelle Morel, Charline Bottinelli, Caroline Solas, Brendan Le Daré, & Nicolas Fabresse. (May 2024). Severe 25E-NBOH intoxication associated with MDPHP intake: a case report, metabolism study, and literature review. International Journal of Legal Medicine, 138(3), 815–822. https://doi.org/10.1007/s00414-023-03151-6123
- Neurotoxic effects of hallucinogenic drugs 25H-NBOMe and 25H-NBOH in organotypic hippocampal cultures. (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10336585/1
- Misuse of Drugs Act 1971, Schedule 2, Part I (Class A Drugs) — N-benzyl catch-all clause (as amended by S.I. 2014/1106). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
- Misuse of Drugs Act 1971, Schedule 4 — Prosecution and punishment of offences. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/41
- 21 U.S.C. § 813 — Treatment of controlled substance analogues. Cornell Legal Information Institute / U.S. Code (n.d.). https://www.law.cornell.edu/uscode/text/21/8131
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
2 August 2026
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25E-NBOH article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.